Design of tumor biomarker-monitoring trials: A proposal by the European Group on Tumor Markers

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 52-59

  Sölétormos, György ^a   Duffy, Michael J ^b   Hayes, Daniel F ^c   Sturgeon, Catharine M ^d   Barak, Vivian ^e   Bossuyt, Patrick M ^f   Diamandis, Eleftherios P ^g,h   Gion, Massimo ⁱ   Hyltoft Petersen, Per ^j   Lamerz, Rolf M ^k   Nielsen, Dorte L ^a   Sibley, Paul ^l   Tholander, Bengt ^m   Tuxen, Malgorzata K ^a   Bonfrer, Johannes M G ⁿ  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g MOUNT SINAI HOSPITAL   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ Centre for the Study of Biological Markers of Malignancy   (Italy)

^j UNIVERSITY OF BERGEN   (Norway)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l Siemens Healthcare Limited   (United Kingdom)

^m UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁿ NETHERLANDS CANCER INSTITUTE   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER RESEARCH; CANCER THERAPY; CLINICAL EFFECTIVENESS; DRUG MONITORING; DRUG RESEARCH; ECONOMIC ASPECT; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TREATMENT OUTCOME; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; EUROPE; HUMANS; MONITORING, PHYSIOLOGIC; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872009094     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.180778     Document Type: Article

References (33)

1. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66. (Pubitemid 26340047)
2. Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Wittliff JL. Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, eds. Tumor biomarkers: physiology, pathobiology, technology, and clinical applications. Washington (DC): AACC Press; 2002. p 33-63.
3. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48.
4. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79. (Pubitemid 352777353)
5. EQUATOR network. Library for health research reporting. http://www.equator-network.org/resource-centre/library-of-health-research- reporting/ (Accessed June 2012).
6. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
7. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, and for the Statistics Subcommittee of the NCI EORTC Working Group on Cancer Diagnostics. J Natl Cancer Inst 2005;97:1180-4.
8. Sargent D, Allegra C. Issues in clinical trial design for tumor marker studies. Semin Oncol 2002;29:222-30. (Pubitemid 34620439)
9. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 2006;11:541-52. (Pubitemid 43967610)
10. European Group on Tumor Markers. http://www.egtm.eu/ (Accessed June 2012).
11. Dignam JJ, Karrison TG, Bryant J. Design and analysis of oncology clinical trials. In: Chang AE, Ganz PA, Dayes DF, Kinsella TJ, Pass HI, Schiller JH, et al., eds. Oncology: an evidence-based approach. New York: Springer; 2006. p 112-26.
12. Price CP, Glenn JL, Christenson RH. Applying evidence-based laboratory medicine. A step-by-step guide. Washington (DC): AACC Press; 2009.
13. Straus SE, Glasziou PP, Richardson WS, Haynes RB. Evidence-based medicine. How to practice and teach EBM. 4th ed. Edinburgh: Churchill Livingstone; 2010.
14. National Institute for Health and Clinical Excellence (NICE). http://www.nice.org.uk/ (Accessed June 2012).
15. Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle - Will we get our wish? N Engl J Med 2008;358:105-7.
16. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52.
17. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al., for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003;138:40-4. (Pubitemid 36232093)
18. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999;45:1695-707. (Pubitemid 29477325)
19. Fraser CG. Biological variation: from principles to practice. Washington (DC): AACC Press; 2001.
20. Sturgeon C, Hill R, Hortin GL, Thompson D. Taking a new biomarker into routine use - a perspective from the routine clinical biochemistry laboratory. Proteomics Clin Appl 2010;4:892-903.
21. Westgard QC: Tools, technologies and training for healthcare laboratories. Desirable specifications for total error, imprecision, and bias, derived from intra- and inter-individual biologic variation. http://www.westgard.com/biodatabase1.htm (Accessed June 2012).
22. Sölé tormos G, Semjonow A, Sibley PE, Lamerz R, Petersen PH, Albrecht W, et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005;51:1342-51.
23. Sölé tormos G, Petersen PH, Dombernowsky P. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer. Clin Chem Lab Med 2000;38:453- 63.
24. Tuxen MK, Sölé tormos G, Petersen PH, Schioler V, Dombernowsky P. Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol Oncol 1999;74:12-22. (Pubitemid 29331162)
25. Petersen PH, Sölé tormos G, Pedersen MF, Lund F. Interpretation of increments in serial tumour biomarker concentrations depends on the distance of the baseline concentration from the cut-off. Clin Chem Lab Med 2011;49:303-10.
26. Sölé tormos G, Hyltoft Petersen P, Dombernowsky P. Progression criteria for cancer antigen 15.3 and carcinoembryonic antigen in metastatic breast cancer compared by computer simulation of marker data. Clin Chem 2000;46:939-49.
27. Sölétormos G, Nielsen D, Schioler V, Skovsgaard T, Dombernowsky P. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem 1996;42:564-75.
28. National Comprehensive Cancer Network (NCCN). http://www.nccn.org/index. asp (Accessed June 2012).
29. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010;102:152-60.
30. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 2007;60:1205-19. (Pubitemid 350061148)
31. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376:1155-63.
32. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7. (Pubitemid 13014028)
33. Bast RC Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 2010;116:2850-3.